Publications by authors named "A C Ek"
Article Synopsis
- The study looked at how safe and effective a medicine called Omnitrope (a type of human growth hormone) is for kids with a condition called Prader-Willi syndrome (PWS).
- 235 kids were part of the study, and researchers watched for any side effects while they were treated.
- After 3 years of treatment, most kids saw improvements in their height, which means the medicine really helped them grow!
Research facilities such as spallation sources and synchrotrons generate radiation for use in atomic-level or molecular-scale experiments. These facilities can be viewed as complex safety-critical systems. An important aspect of the safety management of such systems is the short safety education and training programme the users are required to undergo in order to gain facility access.
View Article and Find Full Text PDFWeight-related discussions during childhood may have long-lasting effects on children's body image and well-being. However, little is known about how parents frame these discussions with children who have undergone treatment for obesity. Our study aimed to explore how parents perceive weight-related discussions, several years after their children started obesity treatment.
View Article and Find Full Text PDFArticle Synopsis
- Early childhood obesity interventions that support parents show significant impacts on children's weight status, but data on long-term effects is limited.
- This study aimed to evaluate the weight status of young children 48 months after starting obesity treatment involving 171 families in Sweden.
- Results indicated that all treatment groups experienced reductions in BMI-SDS after 48 months, with the parent support program showing the greatest clinically significant reduction, demonstrating its effectiveness over standard outpatient treatment.
- Nonetheless, no major differences in outcomes were found between the types of interventions, and factors like sociodemographics and attendance did not influence the results.
Absorption, Metabolism, and Excretion of [C]-Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Male Subjects.
Antimicrob Agents Chemother
April 2023
Article Synopsis
- Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral medication that converts to the active form, tebipenem (TBP), in the gut, targeting multidrug-resistant Gram-negative bacteria.
- A study involving 8 healthy male subjects administered a 600 mg dose of TBP-PI-HBr to evaluate its absorption and metabolism, tracking the substance through blood, urine, and feces.
- Findings indicated that about 83.3% of the administered dose was recovered through urine (38.7%) and feces (44.6%), with TBP being the primary metabolite in plasma, constituting roughly 54% of total plasma radioactivity.